EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Critical Analysis of Shilajatu in Diabetic Peripheral Neuropathy – A Review Article

Rakesh Moolya, Mythrey RC

RGUHS Journal of AYUSH Sciences · 2025 · 12 (1)

DOI: 10.26463/rjas.12_1_10 ↗
AbstractBibliografische Angaben

Abstract

Diabetic peripheral neuropathy DPN is the most prevalent consequence of diabetes mellitus DM. The conventional systems inability to provide adequate therapy causes the disease to worsen which may result in non-traumatic amputation and neuropathic condition. Purvarupa and Prameha Janya Upadrava are the two broad headings that can be used to compare the symptomatology that corresponds to the clinical presentation of DPN as it arises due to DM. Vataja nanatmaja vikaras deal with additional lakshanas such as Pada supti and Padaharsha. The concept of Avarana Vata helps in understanding the condition better. If the drug possesses Rasayana property it will be an added advantage. Shilajatu Asphalthum punjabianum is Laghu Sheeta virya Katu vipaka and Anamla panchrasa. Its Katu vipaka makes it a Srotosodhaka which clears the microchannels. With these attributes Shilajatu aids in dosha pachana toxic metabolites eliminates Avrana and aids in Srotoshodhana. It pacifies Vata and prevents the deterioration of nerve tissue. Shilajatu Ojovardhana property assures Dhatu poshana at the cellular level which in turn may promote nerve cell regeneration. Further experimental studies have shown presence of fulvic acid in Shilajatu which reduces the risk of degeneration. Further Shilajatu is a Rasayana for Prameha and also a Rasayana for Vata vyadhi. Hence due to the above qualities Shilajatu can be used as an ideal therapeutic agent to manage diabetic peripheral neuropathy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →